Rx for Antipsychotc Drugs for Children Begin To Decelerate_WSJ
This is a result of public awareness–thanks to information uncovered during litigation, by Sen. Charles Grassley’s investigative team, by whistleblowers, and the press!
This is a result of public awareness–thanks to information uncovered during litigation, by Sen. Charles Grassley’s investigative team, by whistleblowers, and the press!
Given the serious charges against Dr. Kuklo–including fraud, forgery, and conducting an unapproved experiment on soldiers–the University of Washington’s failure to take action until a series of articles in The New York Times and pressure brought to bear by Sen. Charles Grassley, speaks volumes about a pervasive culture of arrogance in academia.
Two news reports: Alaska Supreme Court decision and a JAMA report confirms that risk of violence among schizophrenia patients "was mostly confined to patients with substance abuse comorbidity."
The Japanes Ministry of Health, Labor and Welfare has investigated news reports about antidepressant users "who developed increased feelings of hostility or anxiety, and have even committed sudden acts of violence against others."
Evidence of harm has been linked to various vaccines challenging prevailing public recommendations.
Colonel Coots: "It is a significant breach of academic protocol. It’s a breach of trust."
Two important analyses in Open Medicine , a peer-reviewed, independent, open-access journal, focus on methodological flaws in data analysis of randomized drug trials.
"William Weeks, MD a professor of psychiatry and community and family medicine is facing federal conflict of interest charges" involving contract between the Veterans Affairs department and Dartmouth.
Sen. Charles Grassley’s focused investigation is clearly aimed at cleansing fraudulent, industry-crafted promotional pieces that have made a mockery of evidence-based clinical practice in psychiatry.
Forbes Magazine reports "How one company turned a rejection into a thumbs up, and what it could mean for the drug industry as a whole."
The FDA has just approved the anitpsychotic drug, Fanapt (iloperidone) for adults with schizophrenia.
The drug, iloperidone, has a long history of failure. http://en.wikipedia.org/wiki/Iloperidone :
The latest QuarterWatch report (May 7, 2009) by the Institute for Safe Medication Practices (ISMP) found the following disturbing trends during the third Quarter of 2008: